How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across ...
SYDNEY, Feb 3 (Reuters) - Sleep-breathing device maker ResMed (RMD.N), opens new tab plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style ...
Sydney: Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for apnea, calling ...
ResMed dominates the global sleep apnea device market, boasting a 50–60% share and a high-margin razor-razor-blade business model. I rate RMD a strong sell due to the imminent threat from Apnimed's ...
Mick Farrell: Thank you, Sally, and good morning, good afternoon, good evening to all of our shareholders, and welcome to all to ResMed's second quarter fiscal year 2026 earnings call. We delivered ...
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...
RMD is trading near the top of its 52-week range and above its 200-day simple moving average. Price change The price of RMD shares has increased $4.58 since the market last closed. This is a 1.72% ...
Chief Strategy Officer Kylie Canaday [Image courtesy of Resmed] Resmed (NYSE: RMD) + announced today that it appointed Kylie Canaday as its new chief strategy officer (CSO). Canaday’s appointment goes ...
SAN DIEGO – Resmed reported revenue increased 11% to $1.4 billion for its second quarter of fiscal year 2026. Other financial results: Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results